PCN35 A COST UTILITY ANALYSIS OF FULVESTRANT VERSUS EXEMESTANE IN THE SECOND LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER IN GREECE (PRELIMINARY RESULTS)
Abstract
Authors
M Pangali A Christodoulopoulou A Ardavanis V Barbounis E Galani D Skarlos